NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
March 27 2024 - 8:30AM
Business Wire
Insights from 11 Abstracts Highlight Key
Findings Across the Oncology Care Spectrum
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology
testing services company, alongside research collaborators, will
present key findings from 11 abstracts at the American Association
for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April
5-10 (booth #915), demonstrating its commitment to advancing cancer
patient care through innovative research and development
initiatives.
The breadth of data highlights NeoGenomics’ comprehensive
approach to addressing various aspects of cancer diagnosis,
treatment, and management. Presentations include research in key
areas, including tumor microenvironment using spatial biology,
next-generation sequencing liquid biopsy assay for clinical
diagnostics and clinical trial applications, comprehensive
multi-omics approaches to identifying genetic alterations in
cancerous cells, and more. Through collaborations with leading
institutions, the company continues to contribute to the broader
landscape of oncology research, emphasizing the connection and
importance of collective efforts in advancing cancer care.
“Our presence at the AACR 2024 Annual Meeting reflects our
dedication and investment in advancing the field of precision
oncology through groundbreaking research and collaborative
partnerships," said Chris Smith, CEO of NeoGenomics. “We are driven
by a steadfast commitment to improving outcomes for cancer
patients. We understand the urgency of the fight against cancer,
and it requires a balance of determination and exploration. As
leaders in oncology, our goal is to provide precise diagnostic
testing, help bring new therapies to market, and identify the
unique hallmarks of each patient’s disease to enable precision
oncology care.”
NeoGenomics is focused on transforming cancer care through
innovation, precision, and compassion. By leveraging genomic and
molecular analysis, NeoGenomics empowers healthcare providers with
actionable insights to tailor treatment strategies and enhance
patient outcomes.
Poster presentations are outlined below, and further details can
be found on the AACR website.
- 94 / 30 - Interrogation of STING induced cytokines in the tumor
microenvironment using an Integrated MultiOmyx-RNA scope panel for
spatial and quantitative profiling
- Presentation: April 7, 2024, 1:30 p.m. – 5:00 p.m. | Section 3
| Poster Board #30
- 949 / 17 - A single stranded DNA library preparation workflow
used for hybridization capture based WES assay showed superior
uniformity
- Presentation: April 7, 2024, 1:30 p.m. – 5:00 p.m. | Section 39
| Poster Board #17
- 1312 / 26 - A study of the clinical utility of NTRKs only vs.
comprehensive gene fusion panel testing from a single assay
platform
- Presentation: April 8, 2024, 9:00 a.m. – 12:30 p.m. | Section 1
| Poster Board #26
- 2352 / 30 - Development of an AI-based algorithm to quantify
eosinophils in H&E images from colorectal cancer (CRC) tissue
sections guided by biomarker staining using multiplex
immunofluorescence imaging
- Presentation: April 8, 2024, 9:00 a.m. – 12:30 p.m. | Section
37 | Poster Board #30
- 5487 / 9 - Improved spatial biology analysis of the tumor
microenvironment with the next generation of the MultiOmyx™
platform
- Presentation: April 9, 2024, 1:30 p.m. – 5:00 p.m. | Section 10
| Poster Board #5
- 5494 / 16 - Spatial organization between claudin and the tumor
microenvironment in head and neck squamous cell carcinomas
- Presentation: April 9, 2024, 1:30 p.m. – 5:00 p.m. | Section 10
| Poster Board #16
- 5038 / 25 - Validation of a comprehensive next-generation
sequencing liquid biopsy assay for clinical diagnostics and
clinical trial applications
- Presentation: April 9, 2024, 9:00 a.m. – 12:30 p.m. | Section
40 | Poster Board #35
- 5054 / 8 - Optimization and evaluation of an FFPE dual
extraction protocol for next-generation sequencing applications
- Presentation: April 9, 2024, 9:00 a.m. – 12:30 p.m. | Section
41 | Poster Board #8
- 6418 / 30 - Single-cell double expression of MYC and BCL2
proteins by fluorescent multiplex IHC is mainly in lymphoma cells
with significant prognostic impact in large B-cell lymphoma while
suggesting high cutoffs for routine IHC
- Presentation: April 9, 2024, 1:30 p.m. – 5:00 p.m. | Section 43
| Poster Board #30
- 6463 / 10 - Highly frequent gene mutations and co-occurring
genes analysis in colorectal cancer
- Presentation: April 9, 2024, 1:30 p.m. – 5:00 p.m. | Section 45
| Poster Board #10
- 6843 / 20 - Comprehensive multi-omics approaches for
identification of genetic alterations in head and neck squamous
cell carcinoma
- Presentation: April 10, 2024, 9:00 a.m. – 12:30 p.m. | Section
8 | Poster Board #20
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus or physicians to help them diagnose
and treat cancer. The Company’s Advanced Diagnostic Division also
serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240326587441/en/
Investor Contact Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact Andrea Sampson
asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Jun 2024 to Jul 2024
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Jul 2023 to Jul 2024